CXCL13 and Tumor Lysis Syndrome: In muscle‐invasive bladder cancer, elevated CXCL13 expression correlated with TLS presence and improved outcomes following anti‐PD‐L1 therapy, irrespective of CD8A expression level, but was associated with the B‐cell marker CD19 [23].